ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
AbbVie Inc

AbbVie Inc (ABBV)

193.41
-0.06
( -0.03% )
Updated: 10:07:04

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
193.41
Bid
-
Ask
-
Volume
264,438
192.20 Day's Range 194.30
135.85 52 Week Range 199.95
Market Cap
Previous Close
193.47
Open
193.59
Last Trade
1
@
193.4988
Last Trade Time
10:07:07
Financial Volume
$ 51,028,590
VWAP
192.97
Average Volume (3m)
4,707,631
Shares Outstanding
1,766,343,745
Dividend Yield
3.21%
PE Ratio
70.27
Earnings Per Share (EPS)
2.75
Revenue
54.5B
Net Profit
4.86B

About AbbVie Inc

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira, administered via injection. AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira, administered via injection.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
AbbVie Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker ABBV. The last closing price for AbbVie was $193.47. Over the last year, AbbVie shares have traded in a share price range of $ 135.85 to $ 199.95.

AbbVie currently has 1,766,343,745 shares outstanding. The market capitalization of AbbVie is $341.73 billion. AbbVie has a price to earnings ratio (PE ratio) of 70.27.

AbbVie (ABBV) Options Flow Summary

Overall Flow

Bullish

Net Premium

780k

Calls / Puts

320.00%

Buys / Sells

90.00%

OTM / ITM

90.91%

Sweeps Ratio

4.76%

ABBV Latest News

AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer

AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer PR Newswire NORTH CHICAGO, Ill., Sept. 20, 2024 NORTH CHICAGO...

Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China

Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China PR Newswire IRVINE, Calif., Sept. 11, 2024 BOTOX® Cosmetic is the first...

Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age

Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age Canada NewsWire MONTREAL, Sept. 10, 2024...

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs PR Newswire NORTH CHICAGO, Ill., Sept. 9, 2024 Full data from the primary...

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend PR Newswire NORTH CHICAGO, Ill., Sept. 6, 2024 NORTH CHICAGO, Ill., Sept. 6, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today...

AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia Canada NewsWire MONTREAL, Sept. 4, 2024...

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases PR Newswire NORTH CHICAGO, Ill., Aug. 27, 2024 More than 400 undergraduate and graduate students in...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.25-1.14995400184195.66196.16191.825048188193.70405776CS
4-4.37-2.20952573567197.78199.95191.274456236195.15910438CS
1222.0512.8676470588171.36199.95163.524707631185.85012316CS
2614.428.05631599531178.99199.95153.585182701174.70178894CS
5240.6726.6269477544152.74199.95135.855314830166.42404266CS
15686.4280.7739041032106.99199.95106.445856958150.76348383CS
260121.08167.39941932872.33199.9562.556833725123.32726061CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AMPXAmprius Technologies Inc
$ 1.09
(22.61%)
558.54k
BHVNBiohaven Ltd
$ 48.48
(20.03%)
2.33M
DNMRDanimer Scientific Inc
$ 0.3736
(14.95%)
125.97k
MPLNChurchill Capital Corp III
$ 8.56
(13.77%)
37.94k
BFAC.UBattery Future Acquisition Corp
$ 12.13
(9.97%)
1
MNSOMINISO Group Holding Limited
$ 14.015
(-14.85%)
5.06M
LICYLi Cycle Holdings Corp
$ 1.9303
(-12.26%)
317.29k
NEUENeuehealth Inc
$ 4.91
(-8.40%)
9.38k
FREYFREYR Battery Inc
$ 0.930301
(-7.89%)
675.95k
KEPKorea Electric Power Corporation
$ 7.575
(-7.73%)
48.43k
PLTRPalantir Technologies Inc
$ 37.495
(0.79%)
19.75M
NIONIO Inc
$ 5.115
(-3.13%)
11.74M
BABAAlibaba Group Holding Limited
$ 89.99
(1.93%)
6.6M
CCLCarnival Corp
$ 18.795
(-1.08%)
6.47M
FFord Motor Company
$ 10.74
(-1.29%)
5.57M

ABBV Discussion

View Posts
Just the facts maam Just the facts maam 2 weeks ago
Whether it involves ANIP or not, AbbVie must be working on some type of deal. This past week was the first time, since spinning off from Abbott Laboratories, that AbbVie did not present at the Morgan Stanley Global Healthcare Conference. Obviously something more important appears to be in the works, which justified the new CEO missing an opportunity to lay out his vision and address questions.
👍️ 1
Just the facts maam Just the facts maam 3 weeks ago
Good point Dew Diligence. I checked the SEC website and went through and checked ANIP's filings. They had three NDAs under review two were filed in Q3 2023, only one showed up as an expense in the 10-Q filing for that quarter. ANIP filed another NDA in Q1 2024 and the related 10-Q filing shows it paid the submission fee that quarter. To date the second NDA filed in Q3 2023 does not show up in any of ANIP's SEC filings. The PDUFA date is likely sometime this month.

I checked the SEC website this time and found neither their 10-k filing or any 10-Q filing showed expenses for an NDA submission related to the second NDA filed in Q3 2023.

The following is from 10-k.
For the year ended December 31, 2023, other operating expenses increased to $258.3 million from $212.9 million for the same period in 2022, an increase of $45.4 million, or 21.3%, primarily as a result of the following factors:
•Research and development expenses increased from $22.3 million to $34.3 million, an increase of 53.6%, primarily due to expenses related to a 505(b)(2) filing for one product of approximately $1.6 million, expenses related to ANDA filings, and a higher level of activity associated with ongoing and new projects in the year ended December 31, 2023.

No mention of expenses for the second NDA from 2023 Q3.

I also checked their Q1 2024 10-Q filing. Here they apparently filed a third NDA:

For the three months ended March 31, 2024, other operating expenses, net increased to $68.0 million from $59.2 million for the same period in 2023, an increase of $8.8 million, or 14.8%, primarily as a result of the following factors:
•Research and development expenses increased from $5.9 million to $10.5 million, an increase of $4.6 million or 77.4%, primarily due to expenses related to a FDA filing fee for a 505(b)(2) for one product of approximately $2.0 million, and a higher level of activity associated with ongoing and new projects in the three months ended March 31, 2024.

Still no accounting for the expense to file the NDA in Q3 of 2023. Q2 10-Q filing made no mention of NDA research expenses.

As stated it looks like another company is financing the regulatory process for this one NDA. And ANIP has not provided info or indications for any of the three NDAs and no PDUFA dates. Though Tezruly (an oral solution terazosin) was approved July 29th. It is the first FDA approved oral solution for an alpha-1 blocker and has patent protection to 2041. This was likely one of the two NDAs filed in Q3 2023.

The lack of info surrounding the three NDA filings, the likelihood that they have a yet to be disclosed a partner for one of the NDA's and the Certification (related to NDA filings) to delay submitting clinical trial results point to the possibility of the FDA reviewing an NDA for the first female testosterone. If so, then AbbVie may be their partner, assuming Dr. Snabes is still involved.

JMHO
👍️0
DewDiligence DewDiligence 3 weeks ago
Could be a timing issue—i.e. the filing fee for the other 505b2 submission might be charged in 3Q24 rather than 2Q24.

p.s. The document you linked to contains edited changes in red. It cannot be the ANIP's actual 10-Q filing.
👍️0
Just the facts maam Just the facts maam 3 weeks ago
ANIP never confirmed the submission fee for one of the NDAs filed in Q3, They announced they filed two NDAs and in the 10 Q filing they said R&D was increased by paying for one NDA. Process of elimination points to another party funding the regulatory process for one of the NDAs

The following is from their earnings release.

Company’s strong R&D organization delivered five new product launches and filed three new ANDAs and two new 505(b)(2) applications in the quarter; retained number two ranking in Competitive Generic Therapy (CGT) approvals

ANIP's press release

From ANIP's 10-Q filing
Research and development expenses increased from $7.7 million to $11.1 million, an increase of $3.5 million or 45.2%, primarily due to expenses related to a 505(b)(2) filing for one product of approximately $1.6 million, and a higher level of activity associated with ongoing and new projects in the three months ended September 30, 2023.

ANIP's 10-Q filing -see Other Operating Expenses on page 43

The $3.2 million NDA submission fee assumes that it relates to the Libigel clinical trials having to be reviewed. Which is consistent with the certification request to delay submitting trial results.

FDA user fee table
👍️0
DewDiligence DewDiligence 3 weeks ago
What is your source for the $3.2M payment by a third party?
👍️0
Just the facts maam Just the facts maam 3 weeks ago
Dew Diligence, I believe in the past that AbbVie had no interest in Female Testoterone (ANIP's Libigel).

I am wondering if that may have changed. In Q3 2023 ANIP filed an NDA for an undisclosed drug where the application fee (approx. $3.2 million) was paid for by an undisclosed. It appears that a Certification request to delay submitting results for Libigel was filed October 27, 2021. For your followers info a Certification is requested to delay posting results when an NDA has been or will be filed.

Seeing that the study director for all Libigel trials was Dr. Michael C. Snabes, who is a Sr. Director with AbbVie Global Research and Development. According to Snabes 4,000 years of data showed that restoring testosterone in post menopausal women at risk of CV events reduced the risk of a CV event by at least 70%. It also showed that it reduced the risk of breast cancer events by an undisclosed amount. They could be sitting on 10 year of safety and efficacy data regarding HSDD and maybe more indications.

https://clinicaltrials.gov/study/NCT00612742?term=biosante&rank=2&tab=results

If AbbVie is ANIP's partner for the first FDA approved female testosterone the application may have been assisted by the Intrinsa portfolio which AbbVie received in their merger with Allergan.

ANIP has never been announced the PDUFA or the fact that another party paid for the NDA filing.

Just trying to figure out who their partner might be. I am leaning toward AbbVie. However, they also have ties to Merck.
👍️0
Monksdream Monksdream 4 weeks ago
ABBV new 52 week high
👍️0
Monksdream Monksdream 1 month ago
ABBV new 52 week high
👍️0
Monksdream Monksdream 2 months ago
ABBV new 52 week high
👍️0
DewDiligence DewDiligence 2 months ago
According to ABBV’s 2Q24 CC, the 8% YoY growth in Botox sales was overstated by about 2x due to inventory restocking. Some of the YoY growth was also due to a price increase. Hence, the YoY change in Botox volume — excluding the restocking effect — was essentially nil.
👍️ 2
DewDiligence DewDiligence 2 months ago
ABBV 2Q24 CC transcript:

https://finance.yahoo.com/news/abbvie-abbv-q2-2024-earnings-193015976.html
👍️0
DewDiligence DewDiligence 2 months ago
ABBV lowered 2024 Botox guidance by $100M compared to the guidance given three months ago. (Source: today's 2Q24 CC.)
👍️ 1
Monksdream Monksdream 2 months ago
ABBV new 52 week high
👍️0
DewDiligence DewDiligence 2 months ago
ABBV reports 2Q24 results:

https://news.abbvie.com/2024-07-25-AbbVie-Reports-Second-Quarter-2024-Financial-Results

2Q24 sales were +6% YoY in constant currency. 2Q24 Humira sales were $2.81B, -30% YoY due to continued uptake of biosimilars in the US market. 2Q24 Skyrizi sales were $2.73B, +46% YoY. 2Q24 Rinvoq sales were $1.43B, +56% YoY. 2Q24 Botox sales (therapeutic + cosmetic) were $1.54B, +8% YoY.

New 2024 non-GAAP EPS guidance is $10.71-10.91, which includes a ($0.60) hit from IPR&D occurring in 1H24, of which the 2Q24 portion ($0.52) was not in the prior full-year 2024 guidance. The midpoint of the new guidance range ($10.81) is -3% from the actual $11.11 in 2023.
👍️0
mrfrederikson mrfrederikson 3 months ago
Cool! Thanks for the good news.
👍️0
DewDiligence DewDiligence 3 months ago
FDA approves ABBV’s Skyrizi for first-line ulcerative colitis:

https://finance.yahoo.com/news/u-fda-approves-skyrizi-risankizumab-221800724.html
• Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND

• Data showed that clinical remission, the primary endpoint in both the induction and maintenance studies, was achieved along with endoscopic improvement, a key secondary endpoint

• SKYRIZI is the first IL-23 antagonist approved for both ulcerative colitis and Crohn's disease ABBV’s Rinvoq, which is oral, is also approved in UC and Crohn’s disease following first-line treatment with a TNF-a agent such as Humira (#msg-171942039). Thus, Skyrizi and Rinvoq together give ABBV a bruising one-two punch in IBD, which accounts for about 40% of the overall market addressed by these agents (and Humira).

ABBV says Skyrizi and Rinvoq will have combined worldwide sales of $27B by 2027, several billion more than the peak annual sales attained by Humira.
👍️ 1
DewDiligence DewDiligence 3 months ago
Mini-tender offers are cropping up more often in drug/biotech industry:

https://finance.yahoo.com/news/abbvie-recommends-shareholders-reject-tutanotas-200800730.html

For a stock like ABBV that has ample trading volume, it makes little sense for a shareholder to tender.
👍️0
DewDiligence DewDiligence 5 months ago
ABBV 1Q24 CC transcript:

https://finance.yahoo.com/news/q1-2024-abbvie-inc-earnings-052453398.html
👍️0
DewDiligence DewDiligence 5 months ago
ABBV reports 1Q24 results—raises 2024 guidance:

https://news.abbvie.com/2024-04-26-AbbVie-Reports-First-Quarter-2024-Financial-Results

New 2024 non-GAAP EPS guidance $11.13-11.33, up from the prior guidance of $11.05-11.25 three months ago. The new guidance includes an ($0.08) hit from IPR&D occurring in 1Q24, which was not in the prior full-year 2024 guidance.

The midpoint of the new range ($11.23) represents 1% YoY growth from the actual $11.11 in 2023. The lack of robust YoY growth is due, in large part, to the continued uptake of Humira biosimilars in the US market.
👍️0
Monksdream Monksdream 6 months ago
ABBV new 52 week hi
👍️0
DewDiligence DewDiligence 7 months ago
ABBV inks drug-discovery collaboration with (private) Tentarix:

https://finance.yahoo.com/news/abbvie-tentarix-announce-collaboration-develop-130500277.html AbbVie and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's proprietary Tentacles™ platform.

Tentacles™ are multi-functional, conditionally-active antibody-based biologics that are designed specifically to activate immune cells that can modulate disease pathways, while potentially mitigating safety concerns associated with non-specific targeting of other immune cells. How are “tentacles” different from ADCs?
👍️0
Monksdream Monksdream 8 months ago
ABBV new 52 week high
👍️0
budgetthis budgetthis 8 months ago
Looking good, Abbvie!

Various Anslysts like us.

How nice. Let’s rock on this week.

$$ ABBV $$
👍️0
DewDiligence DewDiligence 8 months ago
ABBV 4Q23 CC transcript:

https://finance.yahoo.com/news/abbvie-abbv-q4-2023-earnings-204515179.html
👍️0
DewDiligence DewDiligence 8 months ago
ABBV reports 4Q23 results—issues 2024 guidance:

https://news.abbvie.com/2024-02-02-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2023-Financial-Results

2024 non-GAAP EPS guidance is $11.05-11.25, essentially flat relative to $11.11 in 2023. The lack of material YoY growth is due, in part, to the continued uptake of Humira biosimilars in the US market.
👍️ 1
Southern Gal Southern Gal 9 months ago
https://finance.yahoo.com/news/sight-sciences-announces-publication-successful-210500987.html
👍️0
DewDiligence DewDiligence 11 months ago
ABBV 3Q23 CC transcript:

https://finance.yahoo.com/news/abbvie-inc-nyse-abbv-q3-170643822.html
👍️0
DewDiligence DewDiligence 11 months ago
ABBV reports 3Q23 results—raises_2023 non-GAAP EPS guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-third-quarter-2023-financial-results.htm

The new 2023 non-GAAP EPS guidance is $11.19-11.23 (up from the prior range of $10.90-11.20). The sharp decline from 2022’s non-GAAP EPS of $13.77 is due to the launch of Humira biosimilars in the US market.
👍️ 1
DewDiligence DewDiligence 1 year ago
ABBV 2Q23 CC transcript:

https://finance.yahoo.com/news/q2-2023-abbvie-inc-earnings-050609256.html
👍️0
DewDiligence DewDiligence 1 year ago
ABBV reports 2Q23 results—raises_2023 non-GAAP EPS guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2023-financial-results.htm

The new 2023 non-GAAP EPS guidance is $10.90-11.20 (up from the prior range of $10.57-19.97). The sharp decline from 2022’s non-GAAP EPS of $13.77 is due to the launch of Humira biosimilars in the US market. However, the uptake of Humira biosimilars in the US market has been somewhat slower than anticipated, which is the main reason for ABBV’s increasing its 2023 non-GAAP EPS guidance.

Reuters:
https://finance.yahoo.com/news/abbvie-raises-annual-profit-forecast-114058077.html
👍️0
DewDiligence DewDiligence 1 year ago
ABBV’s $21B buyout of PCYC is_looking_worse_lately:

https://www.fiercepharma.com/pharma/abbvie-sues-beigene-over-brand-new-imbruvica-patent-blood-cancer-battle-heats Because of Imbruvica’s toxicity [see #msg-170086344], the National Comprehensive Cancer Network (NCCN) recently downgraded its guidance on Imbruvica, removing the AbbVie/J&J drug from a “preferred” regimen status. The NCCN guidelines committee has instead placed [BGNE’s] Brukinsa above Imbruvica in several areas.

…Facing double pressure from Brukinsa and AstraZeneca’s Calquence, Imbruvica has been on fast decline. First-quarter sales of the first-generation BTK inhibitor dropped 25% year on year to $878 million for AbbVie. The above article is about a new patent-infringement suit by ABBV against BGNE.

Note: The 2015 buyout of PCYC gave ABBV only half the worldwide commercial rights to Imbruvica (#msg-111425234).
👍️0
DewDiligence DewDiligence 1 year ago
ABBV -3% on_announcement_of_low-priced Humira biosimilar from CHRS—including distribution by Mark’s Cuban’s CostPlus pharmacy:

https://www.globenewswire.com/news-release/2023/06/01/2680331/33333/en/Coherus-Announces-Industry-Wide-Lowest-List-Price-for-Adalimumab-Biosimilar-YUSIMRY-adalimumab-aqvh-Launching-in-July-2023.html

https://www.globenewswire.com/news-release/2023/06/01/2680351/33333/en/Mark-Cuban-Cost-Plus-Drug-Company-joins-forces-with-Coherus-to-make-YUSIMRY-a-HUMIRA-biosimilar-available-to-patients.html
👍️0
DewDiligence DewDiligence 1 year ago
ABBV/GMAB—FDA approves Epkinly—(epcoritamab)—for r/rDLBCL:

https://www.businesswire.com/news/home/20230518005495/en/EPKINLY%E2%84%A2-epcoritamab-bysp-Approved-by-U.S.-Food-and-Drug-Administration-as-the-First-and-Only-Bispecific-Antibody-to-Treat-Adults-with-Relapsed-or-Refractory-RR-Diffuse-Large-B-cell-Lymphoma-DLBCL/

Epkinly is a CD20-bispecific mAb. This is an accelerated approval based on a single-arm phase-2 trial.
👍️0
DewDiligence DewDiligence 1 year ago
FDA approves Rinvoq for Crohn’s disease:

https://finance.yahoo.com/news/u-fda-approves-rinvoq-upadacitinib-162500452.html

Rinvoq now has seven FDA–approved indications: RA; psoriatic arthritis; ankylosing spondylitis; axial spondyloarthritis; ulcerative colitis; and Crohn’s disease. In the five non-IBD indications (all except UC and Crohn’s), Rinvoq is indicated for second-line treatment following a TNF-a biologic.

ABBV now has three of the four IBD approvals it seeks: Rinvoq in UC and Crohn’s, and Skyrizi in Crohn’s. Based on phase-3 data (#msg-171517753), ABBV plans to submit a Skyrizi BLA for UC in 2023.

ABBV expects combined sales of Skyrizi and Rinvoq to teach $17.5B in 2025 and $21B in 2027 (#msg-170905881).
👍️0
sunspotter sunspotter 1 year ago
Muddy Waters doesn't like the way Abbvie and Chinook have been presenting data on atrasentan:

https://d.muddywatersresearch.com/content/uploads/2023/05/MW_KDNY_20230516.pdf
👍️0
DewDiligence DewDiligence 1 year ago
ABBV reports 1Q23 results—raises non-GAAP EPS guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2023-financial-results.htm

2023 non-GAAP EPS has been raised $0.10 at both the lower and upper bounds of the range, which is now $10.72-$11.12. This a sharp decline from 2022’s $13.77 due to the launch of Humira biosimilars in the US market.
👍️0
DewDiligence DewDiligence 1 year ago
ABBV—FDA expands Qulipta label_to prevention of chronic migraine:

https://finance.yahoo.com/news/u-fda-approves-qulipta-atogepant-234100408.html

Previously, Qulipta was approved for prevention of episodic migraine, but not chronic migraine. The distinction between the two indications is arbitrary but industry-standard. Chronic migraine is defined as a condition that causes >=15 headache days per month of which >=8 days are migraine.

ABBV’s migraine portfolio also includes Ubrelvy for treatment of acute migraine and Botox for prevention of chronic migraine.

Qulipta’s main competition is PFE’s Nurtec.
👍️0
DewDiligence DewDiligence 2 years ago
Skyrizi phase-3 in UC hits all endpoints:

https://www.prnewswire.com/news-releases/risankizumab-skyrizi-achieves-primary-and-all-secondary-endpoints-in-phase-3-induction-study-in-patients-with-ulcerative-colitis-301779462.html

Skyrizi is currently approved in Crohn’s disease, but not in UC.
👍️0
DewDiligence DewDiligence 2 years ago
ABBV advances Rinvoq to phase-3 in lupus:

https://www.prnewswire.com/news-releases/abbvie-advances-upadacitinib-rinvoq-to-phase-3-clinical-trials-in-systemic-lupus-erythematosus-301779254.html
👍️0
DewDiligence DewDiligence 2 years ago
ABBV receives CRL for ABBV-951 due to FDA questions about the pump delivery device:

https://www.prnewswire.com/news-releases/abbvie-provides-regulatory-update-on-abbv-951-foscarbidopafoslevodopa-new-drug-application-301777945.html
👍️0
DewDiligence DewDiligence 2 years ago
ABBV 4Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2023/02/09/abbvie-abbv-q4-2022-earnings-call-transcript/
👍️0
DewDiligence DewDiligence 2 years ago
ABBV pipeline update:

https://investors.abbvie.com/static-files/9200a822-5d4b-4a1d-a4f3-720cb7b76723
👍️0
DewDiligence DewDiligence 2 years ago
ABBV reports 4Q22 results—issues 2023 guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2022-financial-results.htm

ABBV’s 2023 non-GAAP EPS guidance is $10.70-11.10, a sharp decline from 2022’s $13.77 due to the launch of Humira biosimilars in the US market.
👍️0
DewDiligence DewDiligence 2 years ago
ABBV introduces Juvederm Volux—a_dermal_filler_for jawline augmentation:

https://finance.yahoo.com/news/juv-derm-volux-xc-improvement-130000644.html

This offering expands the Juvederm XC product line, which includes, in ascending order of heaviness: Volbella (for lips); Vollure (for nasolabial folds); Voluma (for mid-face augmentation), and Volux (for jawline).
👍️0
DewDiligence DewDiligence 2 years ago
ABBV JPM slide set:

https://investors.abbvie.com/static-files/4d7aae8a-65ca-45f9-bc0f-a169b5a7dc9d
👍️0
DewDiligence DewDiligence 2 years ago
ABBV now_expects Skyrizi/Rinvoq combined_2025_ sales_>=$17.5B—(up_from_prior_guidance_of_>=$15B):

https://finance.yahoo.com/news/abbvie-raises-sales-outlook-two-141249692.html

ABBV also expects peak combined annual sales of these two drugs will exceed $21B in 2027.

All this despite the JAK limitation of Rinvoq to the second-line setting in most indications.
👍️0
conix conix 2 years ago
ABBV in Investor's Daily

https://www.investors.com/news/technology/abbvie-stock-briefly-breaks-out-on-a-new-cancer-deal/
👍️0
DewDiligence DewDiligence 2 years ago
ABBV’s neurotoxin, AGN-151607 misses primary endpoint in prevention of PAOF (PostOperative Atrial Fibrillation) in cardiac-surgery patients:

https://finance.yahoo.com/news/abbvie-announces-breaking-results-phase-173100778.html

AGN-151607 is a Type-A botulinum toxin that, unlike Botox, is intended for cardiology indications.
👍️0
DewDiligence DewDiligence 2 years ago
ABBV 3Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2022/10/28/abbvie-abbv-q3-2022-earnings-call-transcript/
👍️0
DewDiligence DewDiligence 2 years ago
ABBV 3Q22 results:

https://news.abbvie.com/news/press-releases/abbvie-reports-third-quarter-2022-financial-results.htm
👍️0

Your Recent History

Delayed Upgrade Clock